Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

118.48
+2.151.85%
Post-market: 118.480.00000.00%19:30 EDT
Volume:570.49K
Turnover:68.11M
Market Cap:9.85B
PE:-36.88
High:122.13
Open:119.12
Low:118.27
Close:116.33
52wk High:130.05
52wk Low:47.86
Shares:83.15M
Float Shares:64.87M
Volume Ratio:0.85
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.53
PE(LYR):-32.11

Loading ...

May 03, 2022

Major Issues Report

8-K - Current report
May 03, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 11, 2022

Major Issues Report

8-K - Current report
Feb 24, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 24, 2022

Major Issues Report

8-K - Current report
Feb 24, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 04, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jan 31, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jan 18, 2022

Major Issues Report

8-K - Current report
Dec 27, 2021

Major Issues Report

8-K - Current report
Dec 16, 2021

Major Issues Report

8-K - Current report
Nov 10, 2021

Major Issues Report

8-K - Current report
Nov 10, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 27, 2021

Major Issues Report

8-K - Current report
Sep 16, 2021

Major Issues Report

8-K - Current report
Aug 06, 2021

Major Issues Report

8-K - Current report
Aug 06, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]